Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2003-8-5
pubmed:abstractText
The parasite Leishmania has been used for pioneering work to define T-cell subsets and cytokine patterns mediating susceptibility or resistance to infectious pathogens. This understanding has been essential for the development of a new generation of candidate vaccines for major diseases, such as leishmaniases themselves, tuberculosis and others. It is clear that effective vaccines can be developed through a combination of both antigen and adjuvant selection. Until recently, no adjuvants acceptable for use in human T-cell vaccines were available. However, one such adjuvant, monophosphoryl lipid A, has been shown to be safe and effective. Just as the understanding of T-cell responses has been necessary for the development of a new generation of vaccines, an understanding of signaling by antigen-presenting cells has been essential for adjuvant selection. A combination of antigens and an adjuvant that is effective at promoting durable T-helper 1 responses and is safe for human use comprise a promising vaccine candidate, Leish-111f. This vaccine has potential application in both the prevention and treatment of leishmaniasis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1476-0584
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
239-52
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Development of a leishmaniasis vaccine: the importance of MPL.
pubmed:affiliation
Corixa Corporation, Seattle, WA, USA.
pubmed:publicationType
Journal Article, Review